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ABSTRACT  
Several natural compounds exhibit strong capacity for decreasing triglyceride accumulation, enhancing lipolysis 
and inducing apoptosis. The present study reports the anti-adipogenic effects of Silybum marianum (SL), Citrus 
aurantium (CA), Taraxacum officinale (TO), resveratrol (RE), Curcuma longa (CU), caffeine (CF), oleuropein 
(OL) and docosahexaenoic acid (DHA) in reducing differentiation and increasing lipolysis and apoptosis. Anal-
yses were performed on human primary visceral pre-adipocytes after 10 (P10) and 20 (P20) days of treatment 
during differentiation and on mature adipocytes after 7 days of treatment (A7). The percentage of apoptosis in-
duced by TO extract in P10 and P20 cells was significantly higher than that induced by all other compounds and 
in CTRL cells. Triglyceride accumulation was significantly lower in cells treated with DHA, CF, RE in compari-
son to cells treated with OL and in CTRL cells. Treatments with CF, DHA and OL significantly incremented 
lipolysis in P20 cells in comparison to other compounds and in CTRL cells. On the contrary, the treatment of A7 
cells with OL, CA and TO compounds significantly increased cell lipolysis. The addition of CF in differentiating 
P20 pre-adipocytes significantly increased the expression of genes involved in inhibition of adipogenesis, such 
as GATA2, GATA3, WNT1, WNT3A, SFRP5, and DLK1. Genes involved in promoting adipogenesis such as 
CCND1, CEBPB and SREBF1 were significantly down-regulated by the treatment. The screening of bioactive 
compounds for anti-adipogenic effects showed that in differentiating cells TO extract was the most effective in 
inducing apoptosis and CF and DHA extracts were more efficient in inhibition of differentiation and in induction 
of cell lipolysis. 
 
Keywords: natural compounds, apoptosis, differentiation, lipolysis, visceral adipocytes 
Abbreviations: ACACB, acetyl-CoA carboxylase beta; ADIG, adipogenin; ADIPOQ, adiponectin; ADRB2, 
adrenoceptor beta 2; AGT, angiotensinogen; ANGPT2, angiopoietin 2; AXIN1, axin 1; BMP2, bone morphoge-
netic protein 2; BMP4, bone morphogenetic protein 4; BMP7, bone morphogenetic protein 7; CCND1, cyclin 
D1; CDK4, cyclin-dependent kinase 4; CDKN1A, cyclin-dependent kinase inhibitor 1A (p21, Cip1); CDKN1B, 
cyclin-dependent kinase inhibitor 1B (p27, Kip1); CEBPA, CCAAT/enhancer binding protein (C/EBP) alpha; 
CEBPB, CCAAT/enhancer binding protein (C/EBP) beta; CEBPD, CCAAT/enhancer binding protein (C/EBP) 
delta; CFD, complement factor D (adipsin); CREB1, cAMP responsive element binding protein 1; DDIT3, 
DNA-damage-inducible transcript 3; DIO2, deiodinase, iodothyronine, type II; DKK1, dickkopf WNT signaling 
pathway inhibitor 1; DLK1, delta-like 1 homolog (Drosophila); E2F1, E2F transcription factor 1; EGR2, early 
growth response 2; FABP4, fatty acid binding protein 4, adipocyte; FASN, fatty acid synthase; FGF1, fibroblast 
growth factor 1 (acidic); FGF10, fibroblast growth factor 10; FGF2, fibroblast growth factor 2 (basic); FOXC2, 
forkhead box C2 (MFH-1, mesenchyme forkhead 1); FOXO1, forkhead box O1; GATA2, GATA binding pro-
tein 2; GATA3, GATA binding protein 3; HES1, hes family bHLH transcription factor 1; INSR, insulin recep-
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tor; IRS1, insulin receptor substrate 1; IRS2, insulin receptor substrate 2; JUN, jun proto-oncogene; KLF15, 
Kruppel-like factor 15; KLF2, Kruppel-like factor 2; KLF3, Kruppel-like factor 3; KLF4, Kruppel-like factor 4; 
LEP, leptin; LIPE, lipase, hormone-sensitive; LMNA, lamin A/C; LPL, lipoprotein lipase; LRP5, low density 
lipoprotein receptor-related protein 5; MAPK14, mitogen-activated protein kinase 14; NCOA2, nuclear receptor 
coactivator 2; NCOR2, nuclear receptor corepressor 2; NR0B2, nuclear receptor subfamily 0, group B, member 
2; NR1H3, nuclear receptor subfamily 1, group H, member 3; NRF1, nuclear respiratory factor 1; PPARA, pe-
roxisome proliferator-activated receptor alpha; PPARD, peroxisome proliferator-activated receptor delta; 
PPARG, peroxisome proliferator-activated receptor gamma; PPARGC1A, peroxisome proliferator-activated 
receptor gamma, coactivator 1 alpha; PPARGC1B, peroxisome proliferator-activated receptor gamma, coactiva-
tor 1 beta; PRDM16, PR domain containing 16; RB1, retinoblastoma 1; RETN, resistin; RUNX1T1, runt-related 
transcription factor 1; RXRA, retinoid X receptor, alpha; SFRP1, secreted frizzled-related protein 1; SFRP5, 
secreted frizzled-related protein 5; SHH, sonic hedgehog; SIRT1, sirtuin 1; SIRT2, sirtuin 2; SIRT3, sirtuin 3; 
SLC2A4, solute carrier family 2 (facilitated glucose transporter), member 4; SRC, v-src avian sarcoma 
(Schmidt-Ruppin A-2) viral oncogene homolog; SREBF1, sterol regulatory element binding transcription factor 
1; TAZ, tafazzin; TCF7L2, transcription factor 7-like 2 (T-cell specific, HMG-box); TSC22D3, TSC22 domain 
family, member 3; TWIST1, twist family bHLH transcription factor 1; UCP1, uncoupling protein 1 (mitochon-
drial proton carrier); VDR, vitamin D (1,25- dihydroxyvitamin D3) receptor; WNT1, wingless-type MMTV in-
tegration site family, member 1; WNT10B, wingless-type MMTV integration site family, member 10B; 
WNT3A, wingless-type MMTV integration site family, member 3A; WNT5A, wingless-type MMTV integration 
site family, member 5A; WNT5B, wingless-type MMTV integration site family, member 5B. 
 
 
 
INTRODUCTION 
The remodeling of adipose tissue is a dy-
namic process that is related to adipogenesis 
and apoptosis. The associated changes in ad-
ipocytes number is regulated by the expres-
sion of a battery of genes which controls cell 
fate. In accordance with Rayalam et al. 
(2008), bioactive components of plant ex-
tracts can have direct effects on adipose tis-
sue. According to the Food and Drug Ad-
ministration (FDA) a dietary supplement 
should contain one or many ingredients 
among vitamins, minerals, herbs, amino ac-
ids, concentrates, metabolites or extracts 
(Ross, 2000). Instead, a nutraceutical differs 
since it must not only supplement the regular 
diet, but also aid in the prevention of treat-
ment of disease and disorder (Kalra, 2003). 
In this regard, natural anti-obesity molecules 
can reduce body weight by decreasing lipid 
absorption, energy intake, pre-adipocyte dif-
ferentiation and proliferation and lipogenesis 
or increasing the energy expenditure and li-
polysis (Yun, 2010). As extensively re-
viewed by Colitti and Grasso (2014), several 
nutraceuticals have been considered as anti-
obesity molecules for their capacity to de-
crease triglyceride accumulation, enhance 
lipolysis, induce apoptosis or modify gene 
expression. In recent years, apoptosis was 
considered one of the main targets to reduce 
the number of pre-adipocytes or adipocytes 
thus preventing hyperplasia and hypertrophia 
(Rayalam et al., 2008; Herold et al., 2013).  
Silymarin, a compound of the crude ex-
tract of plant milk thistle plant (Silybum 
marianum SL), is known for its hepatopro-
tective effect and chemopreventive activites 
(Raina and Agarwal, 2007). Silymarin was 
also found to attenuate adipogenesis and to 
decrease glucose uptake, directly inhibiting 
GLUT4-mediated glucose transport (Ka et 
al., 2009; Zhan et al., 2011). 
The bitter orange extract of Citrus au-
rantium (CA) fruits contains protoalkaloids, 
the most representative being p-synephrine 
(known also as oxedrine), which is used for 
the treatment of obesity. The extract also 
contains other protoalkaloids as octopamine, 
hordenine and tyramine (Stohs et al., 2011). 
Also flavonoids, such as limonene, hesperi-
din, neohesperidin and naringin, together 
with furanocoumarins are typically present 
in CA fruit extract (Wichtl, 2004). Octopa-
mine can induce the lipolysis of adipocytes 
in rat, hamster and dog through the agonistic 
activity on the β-adrenergic receptor, even 
though this effect was not confirmed not on 
human adipocytes (Carpéné et al., 1999). In-
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stead, studies on human subcutaneous fat 
cells have been demonstrated that synephrine 
has a lipolytic action (Mercader et al., 2011). 
A recent study conducted on 3T3-L1 cells 
treated with of CA extracts demonstrated its 
anti-adipogenic activity through inhibition of 
Akt and downregulation of C/EBPβ (Kim et 
al., 2012). 
Taraxacum officinale (TO) plant of the 
genus Taraxacum has been used for a long 
time in many traditional herbal medical sys-
tems to treat dyspepsia, heartburn, spleen 
and liver complaints, hepatitis and anorexia. 
It has been reported that TO has also diuret-
ic, anti-inflammatory, anti-oxidative, anti-
carcinogenic, analgesic, anti-hyperglycemic 
and anti-coagulatory properties (Schütz et 
al., 2006). A decrease in body weight was 
observed in mice fed with high fat diet sup-
plemented with TO leaf extract. Moreover, 
TO leaf extract supplement suppressed se-
rum levels of triglyceride, total cholesterol 
and insulin induced by the high fat diet (Da-
vaatseren et al., 2013). 
Caffeine (CF), a xanthine alkaloid, is 
contained in many plants such as Coffea 
canephora, various tea brush and yerba maté 
(Ilex paraguariensis) (Yun, 2010). This nat-
ural compound reduces accumulation of li-
pids in adipocytes and enhances lipolysis by 
inhibiting phosphodiesterase activity (Her-
man and Herman, 2013). A noradrenaline-
like mechanism able to induce lipolysis was 
hypothesized for CF at low concentration. 
The subsequent stimulation of β-adrenergic 
receptors led to an increase of cytosolic 
cAMP and so activates protein kinase A 
(Han et al., 1999). Finally, on 3T3-L1 cells, 
CF allowed differentiation, but reduced lipid 
accumulation on mature adipocytes. More-
over, CF prevented insulin-dependent glu-
cose uptake in mature adipocytes (Naka-
bayashi et al., 2008). 
Curcumin (CU) is extracted from Cur-
cuma longa, a widely used spice in Asia. 
This polyphenol is used to treat cancer, ag-
ing, endocrine, immunological, gastrointesti-
nal and cardiac diseases. The CU extract is 
active also on oxidative stress, inflammation, 
and cell death pathways (Witkin and Li, 
2013). It is demonstrated on 3T3-L1 cells 
that CU decreases differentiation of pre-
adipocytes and reduces accumulation of li-
pids in already mature adipocytes both in 
vivo and in vitro.  
Resveratrol (RE) is a stilbenoid original-
ly found in the berries of the wine grape. In 
the last years it is the most investigated 
among all other phytochemicals. Recent 
studies demonstrated that resveratrol is able 
to prevent adipogenesis in 3T3-L1 cells 
(Hwang et al., 2010; Chen et al., 2011; Vigi-
lanza et al., 2011) through the down-
regulation of proteins related with fatty acid 
metabolism, such as fatty acid synthase 
(FAS) and acetyl-CoA carboxylase (ACAC) 
(Hwang et al., 2010). On human mature adi-
pocytes at a concentration of 100µM, RE 
was able to induce lipolysis and impaired 
lipogenesis (Gomez-Zorita et al., 2013). A 
possible effect of resveratrol on apoptosis 
was also proposed in a recent research. Stud-
ies demonstrated that resveratrol inhibits the 
phosphorylation of protein kinase B (Akt), 
which activates Bax and consequently the 
caspase-dependent intrinsic pathway of 
apoptosis (Rayalam et al., 2008). 
Oleuropein (OL) is the most abundant 
phenolic compound that is found in olive 
pulp, seed, leaves, and peel of unripe olives, 
where can constitute up to 14 % of the dry 
weight (Barbaro et al., 2014). Oleuropein 
supplementation reduces body, liver and 
heart weights in high fat diet-treated mice 
(Poudyal, et al., 2010). On 3T3-L1 cells was 
shown that OL treatment reduces pre-
adipocyte differentiation and lipid accumula-
tion by decreasing the expression of PPARγ 
and C/EBPα and their downstream target 
genes (Drira et al., 2011). 
Docosahexaenoic acid (DHA), a (n-3) 
PUFA present in fish oil, has been demon-
strated to inhibit adipocyte differentiation. 
The suppression of fatty acid synthesis and 
the regulation of adipocytes differentiation 
can be regulated by polyunsaturated fatty 
acids (PUFAs) (Madsen et al., 2005; Okuno 
et al., 1997). This is probably due to the 
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more difficult acetylation process of PUFA 
compared to the acetylation of monounsatu-
rated fatty acids. Moreover, PUFA act as 
signal transducing molecules in adipocytes 
(Okuno et al., 1997; Awad et al., 2000; Ev-
ans et al., 2000). The treatment with DHA of 
3T3-L1 cells for 48 h negatively affected 
droplet size and percentage of lipids in a 
concentration-dependent manner (Kim et al., 
2006). Addition of DHA (50-200 µM) to ful-
ly differentiated 3T3-L1 adipocytes in-
creased basal lipolysis by inducing glycerol 
release (Kim et al., 2006). Moreover, it has 
been observed that DHA (100 µM) treatment 
increased lipolysis in 3T3-L1 cells by an up-
regulation of adipose triglyceride lipase 
(ATGL) and a down-regulation of perilipin 
gene expression (Barber et al., 2013). Other 
studies on 3T3-L1 cells demonstrated that 
DHA inhibits cell proliferation as well 
(Awad et al., 2000). 
The present study describes the anti-
adipogenic effects of Silybum marianum 
(SL), Citrus aurantium (CA), Taraxacum 
officinale (TO), resveratrol (RE), Curcuma 
longa (CU), caffeine (CF), oleuropein (OL) 
and docosahexaenoic acid (DHA) in inhibi-
tion of the pre-adipocyte differentiation and 
in induction of the cell lipolysis and apopto-
sis in human primary visceral adipocytes. 
Moreover, the effect of CF on the differential 
expression of genes involved in adipogenesis 
are reported.  
 
MATERIAL AND METHODS 
Cells 
Human omental pre-adipocyte cells and 
medium were obtained from ZenBio (USA). 
According to the data kindly provided by 
ZenBio, pre-adipocyte cells (OP-F-3) were 
sampled from three Caucasian donor fe-
males, with the mean age of 48.7 ± 9. 1 years 
and the mean BMI of 42. 7 ± 6. 9 kg/cm2. 
Donors were non-diabetic and non-smoking. 
Visceral pre-adipocytes were plated and pro-
liferated in Omental Preadipocyte Medium 
(OM-PM) till the passage 3. All the experi-
ments were run in the humidified 37 °C in-
cubator with 5 % CO2. OM-PM was changed 
each second day till the cells reached full 
confluence. At this time OM-PM was com-
pletely removed, cells were washed with 
phosphate buffered saline (PBS 1X) and fed 
with Omental Differentiation Medium (OM-
DM) and further with Omental Adipocyte 
Medium (OM-AM) added with compounds 
at a concentration of 5, 10, 30 and 70 µg/mL 
with final concentration of 0.0014 % dime-
thyl sulfoxide (DMSO). The control cells 
(CTRL) were incubated in OM-DM and 
OM-AM without compounds in the present 
of 0.0014 % DMSO as well. 
Treatments were performed from the first 
day of differentiation till 10 days in OM-DM 
(P10), till 20 days in OM-DM (P20) and dur-
ing 7 days post differentiation in OM-AM 
(A7). Cells were analyzed at the end of each 
differentiation period. 
Apoptosis, adipogenesis and lipolysis as-
says were performed in a 96 well plate with 
the cell density of 104 cells/well, while PCR 
assay was performed in a 6 well plate with 
the cell density of 105 cells/well. All anal-
yses were performed using cells of three dif-
ferent donors and each donor was assayed in 
triplicate. 
 
Cell treatments 
Cells were treated with the following 
plant extracts: Citrus aurantium (CA), Si-
lybum marianum (SL) and Taraxacum offic-
inale (TO), resveratrol (RE) Curcuma longa 
(CU), provided by ACEF spa (Piacenza, Ita-
ly). Cells were also tested with the following 
bioactive compounds: caffeine (CF), oleuro-
pein (OL) and docosahexaenoicacid (DHA) 
purchased by Sigma (Table 1). Extracts and 
compounds were collectively named com-
pounds if not differentially specified. 
All compounds were suspended in 10 % 
dimethyl sulfoxide (DMSO), with the excep-
tion of DHA that was suspended in 100 % 
ethanol.  
 
Cell viability assay 
The cytotoxicity of compounds at differ-
ent doses (5, 10, 30 and 70 μg/mL) was 
measured using the MTT colorimetric assay 
EXCLI Journal 2016;15:362-377 – ISSN 1611-2156 
Received: March 18, 2016, accepted: June 08, 2016, published: June 20, 2016 
 
 
 
366 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide) (Pomari et al., 2015). At 
the end of each differentiation period (P10, 
P20, A7) cells were washed with PBS, added 
with MTT solution (5 mg/mL in fresh medi-
um) and incubated for 3 hours at 37 °C. 
Then, the mixture was carefully removed 
from each well followed by addition of 
100 µL of DMSO. Absorbance was read 
with a microplate reader at 570 nm. The per-
centage of viable cells was calculated by 
normalizing the absorbance value of the 
treated cells by the absorbance value of the 
CTRL cells.  
Apoptosis assay 
Detection of apoptotic cells was per-
formed using ApoStrandTM ELISA apoptosis 
detection kit (Enzo Life Sciences Inc., NY, 
USA) according to manufacturer's instruc-
tions (Pomari et al., 2015). The apoptotic 
positive control (single stranded DNA in 
PBS) was also included in the analysis. Data 
are expressed as the percentage of cells, 
comparing the optical density of the treat-
ed/CTRL cells with the optical density of the 
positive CTRL included in the kit. 
 
 
Table 1: List of compounds used in the study. SL, Silybum marianum, CA, Citrus aurantium, RE, 
Resveratrol, TO, Taraxacum officinale, CU, Curcuma longa, CF, Caffeine, OL, Oleuropein DHA, Do-
cosahexaenoicacid 
Item Name Origin Extraction Sol-
vent 
Compound  
SL Silybum maria-
num 
Fruit Water / Ethanol 
(40:60 V/V) 
Extract with >=25.0 % 
sylimarine calc.as silybin 
(HPLC) 
CA Citrus 
aurantium L. 
subsp. amara 
Flower Water / Ethanol 
(18: 22 % V/V) 
Extract with > 6.0 % 
sinefrin (HPLC) 
RE Polygonum 
cuspidatum 
Root Water / Ethanol 
(50:1 V/V) 
>=98.0 % Resveratrol, 
3,4′,5-trihydroxy-trans-
stilbene (HPLC) 
TO Taraxacum 
officinale 
Root Water / Ethanol 
(18-22 % V/V) 
Extract with 8.0 % - 12.0 % 
(dried residue of caffeic 
acids, p-hydroxyphenyl-
acetic, chlorogenic acid, 
triterpenes) (TLC) 
CU Curcuma longa Rhizome Water / Ethanol Extract with 20 % 
curcumin, (1E,6E)-1,7-
Bis(4-hydroxy-3-
methoxyphenyl)-1,6-
heptadiene-3,5-dione 
(HPLC) 
CF Caffeine   98.5-101.5 % 1,3,7-
Trimethylxanthine (HPLC) 
OL Oleuropein   >=80 % (2S,3E,4S)-3-
Ethylidene-2-(β-D-
glucopyranosyloxy)-3,4-
dihydro-5-
(methoxycarbonyl)-2H-
pyran-4-acetic acid 2-(3,4-
dihydroxyphenyl) ethyl 
ester  
(HPLC) 
DHA Omega-3 fatty 
acid 
  > 98 % cis-4,7,10,13,16,19-
Docosahexaenoic acid 
(GC) 
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Adipogenesis assay 
Intracellular lipid accumulation in P10 
and P20-treated and in CTRL cells was ana-
lyzed by microscopy (PrimoVert, Zeiss, Jena 
Germany) after staining cells with Oil red O 
(ORO, Sigma, Milan, Italy), and quantified 
using a spectrophotometer at 520 nm. Data 
are expressed as percentage of lipid accumu-
lation relative to the CTRL samples. 
 
Lipolysis assay 
Detection of the lipolytic activity in P20 
and A7 treated cells was performed using 
AdipoLyzeTM Lipolysis Detection Kit (Lon-
za Walkersville Inc., MD, USA), based on 
the quantification of the glycerol release by 
cells undergoing lipolysis (Pomari et al., 
2015). Accumulated glycerol in each sample 
was determined by comparison with a glyc-
erol standard curve. 
 
RNA extraction and adipogenesis PCR  
array on CF-treated P20 cells 
Prior to the total RNA extraction CF-
treated P20 and CTRL cells were rinsed with 
ice-cold PBS followed by the RNA extrac-
tion with miRNeasy kit and QIAzol Lysis 
Reagent (Qiagen, Milan, Italy) according to 
the manufacturer's recommendations. Syn-
thesis of the first strand cDNA was per-
formed using RT2 First Strand kit (Qiagen, 
Milan, Italy) (Stefanon et al., 2015).  
The gene expression profile of adipogen-
esis was determined using ready to use hu-
man Adipogenesis RT2 Profiler PCR Array 
(PAHS-049Z; Qiagen, Milan, Italy) contain-
ing primers for 84 tested, 5 housekeeping 
genes and controls for RT and PCR reac-
tions. The expression of target genes was 
normalized and ΔCts were calculated by the 
difference between Ct of target genes and the 
geometric mean of the four housekeeping 
genes. Differences between CF-treated P20 
cells and P20 CTRL cells were calculated 
using the 2-ΔΔCt method (Livak and 
Schmittgen, 2001; Bustin et al., 2009), where 
2-ΔΔCt represents the difference of a given 
target gene in CF-treated cells vs CTRL. The 
n-fold expression of a given target gene was 
calculated as log2(2-ΔΔCt). 
 
Statistical analysis 
In the cell viability assay, differences be-
tween treated cells were determined by one-
way ANOVA with the concentration (4 lev-
els) as fixed factor (SPSS®, 1997). Signifi-
cant effects of the treatments on cell apopto-
sis, triglyceride accumulation and lipolysis 
were assessed with two-way ANOVA con-
sidering the fixed effect of treatment (treated 
and CTRL cells) and the fixed effect of peri-
od of differentiation (for apoptosis: P10, P20 
and A7 cells; for lipolysis assay: P20 and A7 
cells; for lipid accumulation assay: P10 and 
P20 cells). The effect of interaction (treat-
ment x period of differentiation) was tested 
in two-way ANOVA as well. 
PCR array data, expressed as log2(n-
fold), were analysed using one sample T-test 
(SPSS®, 1997) and P values adjusted for 
multiple testing with false discovery rate 
(FDR). Results are displayed in a form of a 
Volcano plot, which graphically reports the 
relationships of the fold changes with statis-
tical values calculated as the negative Log10 
(P-value). In the plot, the horizontal red line 
illustrates a significant cutoff of P = 0.05. 
 
RESULTS 
Cell viability 
A viability assay was used to find out the 
highest dose of extracts that allowed the cell 
viability to remain over 60 %. Treatment of 
P10, P20 and A7 cells with 5, 10, 30 or 70 
µg/mL compounds, or 25, 50, 100, 200 μM 
DHA showed that cell viability of P20 cells 
significantly (P < 0.001) decreased in a dose-
dependent manner (Table 2). In P10 and P20 
treated cells the viability remained over 70 % 
and 60 % respectively until a compound 
concentration of 30 µg/mL. At a dose of 
70 µg/mL viability was always significantly 
different from other doses (P < 0.001). The 
viability of A7 treated cells remained over 
90 % with the dose up to 70 µg/mL for all 
compounds, except RE. Different doses of 
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Table 2: Modulation of MTT metabolism by compounds in human omental pre-adipocytes and adipo-
cytes. Cells were treated with different concentrations of compounds. P10 differentiating pre-
adipocytes treated for 10 d; P20 differentiating pre-adipocytes treated for 20 d; A7, mature adipocytes 
treated for 7 d. Data are expressed as percentage of absorbance in comparison to CTRL cells (un-
treated) and presented as means ± standard deviation (SD). Different superscript capital letters indi-
cate significant differences (P < 0.001) within treatments at different concentrations. Different super-
script small letters indicate significant differences (P < 0.05) within treatments at different concentra-
tions. 
Compound: SL, Silybum marianum, CA, Citrus aurantium, RE, Resveratrol, TO, Taraxacum officinale, CU, Curcuma longa, CF, 
Caffeine, OL, Oleuropein, DHA, Docosahexaenoicacid 
 
P10  P20  A7   
    
Compound Dose %  SD %  SD %  SD 
           
SL 5 91.33a ± 7.83 90.37A ± 2.47 96.31A ± 1.84 
10 83.79aB ± 7.07 80.19B ± 3.40 95.75A ± 1.70 
30 76.46B ± 6.35 68.61C ± 2.52 94.26A ± 1.34 
70 50.18C ± 9.24 35.44D ± 3.58 85.60B ± 4.34 
    
CA 5 91.49Ab ± 7.83A 89.66A ± 3.14 96.53A ± 2.03 
10 87.81ABb ± 7.25A 78.94B ± 2.73 95.98Ab ± 1.76 
30 83.88B ± 7.01A 66.72C ± 2.54 93.96b ± 2.38 
70 56.49C ± 9.49B 46.28D ± 2.37 83.39C ± 3.53 
    
RE 5 91.51A ± 7.94 92.02A ± 3.08 85.31A ± 2.24 
10 81.57B ± 7.70 78.95B ± 2.91 84.83A ± 1.85 
30 73.89B ± 6.95 68.90C ± 4.71 83.83Ab ± 2.39 
70 48.87C ± 4.55 46.72D ± 2.54 81.69Bb ± 1.52 
    
CU 5 91.29A ± 7.83 91.20A ± 3.76 93.65A ± 3.37 
10 78.43B ± 6.54 80.53B ± 3.45 92.15A ± 1.47 
30 75.60B ± 5.98 70.53C ± 2.65 92.49A ± 1.85 
70 49.79C ± 7.46 42.97D ± 5.19 82.37B ± 2.18 
    
CF 5 91.10A ± 7.66 91.17A ± 3.10 98.08Aa ± 1.70 
10 76.33B ± 6.49 79.75B ± 3.08 96.29Aab ± 2.00 
30 70.58B ± 4.74 70.66C ± 2.12 94.04Bb ± 1.52 
70 49.70C ± 9.16 48.59D ± 11.08 88.92C ± 1.21 
    
TO 5 92.37Aa ± 7.22 90.96A ± 3.17 97.42Aa ± 1.93 
10 85.25Bb ± 6.58 78.69B ± 2.64 94.34aB ± 2.19 
30 81.01Bb ± 6.26 68.78C ± 2.18 93.96B ± 1.57 
70 52.52C ± 8.95 44.71D ± 1.44 89.05C ± 2.30 
    
OL 5 91.46Aa ± 7.77 92.33A ± 3.43 95.70A ± 1.47 
10 82.18aB ± 7.05 81.39B ± 3.39 95.75A ± 1.57 
30 73.59B ± 6.00 70.94C ± 2.09 94.45A ± 2.44 
70 48.68C ± 7.44 52.92D ± 8.58 88.39B ± 3.12 
    
DHA 25 86.40A ± 2.08 89.54A ± 2.80 97.99A ± 3.91 
50 69.08B ± 3.49 77.50B ± 2.45 97.22A ± 4.22 
100 69.57B ± 2.44 65.80C ± 2.40 95.19A ± 3.59 
200 47.35C ± 7.42 43.58D ± 2.40 82.54B ± 3.29 
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DHA showed the same significant (P < 
0.001) dose-dependent decrease in P20 treat-
ed cells, but the cells’ viability at P10 and 
P20 remained over 60 %. According to these 
evidences, the concentration of 30 µg/mL of 
compounds and 50 μM DHA was chosen for 
the experiments. 
 
Effect on apoptosis 
The apoptotic effect of the compounds 
was examined in P10, P20 and A7 cells 
treated with 30 μg/mL extracts or 50 µM 
DHA and in corresponding CTRL cells. A 
significant (P < 0.001) difference of the per-
centage of apoptosis in P10, P20 and A7 
cells under treatments was observed (Figure 
1). 
The interaction of cell apoptosis between 
different stages and treatments was also sig-
nificant (P < 0.001). Interestingly, the per-
centage of apoptosis induced by TO extract 
(76.19 ± 2.4 % at P10 and 81.0 ± 3.4 % at 
P20) was significantly (P < 0.001) higher 
than that induced by all other extracts and in 
CTRL cells. Among the compounds, SL, 
DHA and OL were significantly (P < 0.001) 
less active in inducing apoptosis. 
 
Effect on adipogenesis 
The percentage of apoptosis was affected 
by treatments and was different between ma-
ture adipocytes (A7) and differentiating 
cells. Therefore, the ability of compounds to 
prevent triglyceride accumulation in P10 and 
P20 pre-adipocytes in comparison to CTRL 
cells was evaluated in order to verify the an-
ti-adipogenic effect of studied compounds 
only during differentiation. 
 
 
Figure 1: Modulation of apoptosis by all compounds in human omental pre-adipocytes and mature 
adipocytes. P10, differentiating pre-adipocytes treated for 10 d; P20, differentiating pre-adipocytes 
treated for 20 d; A7, mature adipocytes treated for 7 d. Data are presented as mean percentage ± 
standard error (SE) vs positive CTRL. Capital letters above bars indicate the significant difference for 
P < 0.001 between the mean percentage of apoptosis of the treatments. Capital letter A indicates that 
TO treatment significantly differs from CU, CF, CA, SL, DHA, OL treatments and CTRLs; capital letter 
AB indicates that RE treatment significantly differs from SL, DHA, OL treatments and CTRLs; capital 
letter B indicates that CU, CF and CA treatments significantly differ from TO, SL, DHA, OL and 
CTRLs; capital letter C indicates that SL, DHA and OL treatments significantly differ from TO, RE, CU, 
CF, CA and CTRLs; capital letter D indicates that CTRLs significantly differ from TO, RE, CU, CF, CA, 
SL, DHA, OL. The mean percentage of apoptosis between P10, P20 and A7 is significantly different (P 
< 0.001) as well.  
Compound: SL, Silybum marianum, CA, Citrus aurantium, RE, Resveratrol, TO, Taraxacum officinale, CU, Curcuma longa, CF, 
Caffeine, OL, Oleuropein, DHA, Docosahexaenoicacid 
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Analysis was conducted in P10 and P20 
cells treated with 30 µg/mL extracts and 
50 µM DHA and in the corresponding CTRL 
cells. The amount of triglyceride accumula-
tion was apprised as a percentage respect to 
CTRL, considered as 100 % (Figure 2). Re-
ceived data indicate that adipogenesis was 
inhibited by all tested compounds in P10 and 
P20 cells, showing a significant (P < 0.001) 
decrease of triglyceride accumulation in 
comparison to CTRL cells. Triglyceride ac-
cumulation was significantly (P < 0.001) 
lower in cells treated with DHA, CF, RE 
(57.99 ± 6.0, 67.43 ± 7.9, 74.58 ± 8.7 in P10 
cells and 41.44 ± 3.0, 64.6 ± 6.2, 59.48 ± 5.4 
in P20 cells) in comparison to cells treated 
with OL (88.04 ± 3.9 in 10 cells and 86.54 ± 
3.5 in P20 cells). The effect of days of incu-
bation was not significantly different as well 
as the interaction between days of incubation 
and compounds. 
 
Effect on lipolysis 
To assess if lipolysis is affected by com-
pounds, we measured glycerol release in P20 
pre-adipocytes, when cells were still in ac-
tive development, but TG accumulation is 
reduced in comparison to P10 cells, and on 
mature cells (A7), which contain large lipid 
droplets in the cytoplasm and present round-
ed shape. Treatment of P20 cells with CF, 
DHA and OL extracts significantly (P < 
0.001) incremented the content of free glyc-
erol in the culture medium respectively to
 
 
 
Figure 2: Effects of compounds on triglyceride increment during pre-adipocytes differentiation. Tri-
glyceride accumulation of differentiating pre-adipocytes incubated for 10 d (P10) and 20 d (P20) with 
compounds relative to untreated control cells (CTRL) settled at 100 %. Results are depicted as mean 
percentage ± standard error (SE). Capital letters above bars indicate the significant difference for P < 
0.001 between the mean percentage of the treatments. Capital letter A indicates that OL treatment 
significantly differs from RE, CF and DHA treatments; capital letter AB indicates that OL, SL, TO, CA, 
CU, RE and CF treatments significantly differ from DHA treatment; capital letter BC indicates that RE 
and CF treatments significantly differ from OL treatment; capital letter C indicates that DHA treatment 
significantly differs from OL, SL, TO, CA, CU, RE, CF treatments. The percentage of TG accumulation 
in P10 cells is not significantly different in comparison to P20 cells. 
Compound: SL, Silybum marianum, CA, Citrus aurantium, RE, Resveratrol, TO, Taraxacum officinale, CU, Curcuma longa, CF, 
Caffeine, OL, Oleuropein, DHA, Docosahexaenoicacid 
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221.0 μM (± 9.97), 179.0 μM (± 13.8) and 
169.4 μM (± 8.4) as compared to other com-
pounds and CTRL cells (Figure 3). The 
mean free glycerol of TO (125.0 μM ± 5.8) 
and CU (126.0 μM ± 8.6) treated cells signif-
icantly (P < 0.001) differed from cells treated 
with other compounds showing a decrease of 
release in the culture media. On the contrary, 
the treatment of A7 cells significantly (P < 
0.001) increased the release of free glycerol, 
in particular with OL (102.5 ± 1.6 μM), CA 
(100.4 ± 1.7 μM) and TO (100.3 ± 3.4 μM) 
compounds (Figure 3). The interaction be-
tween different cell stages of differentiation 
and treatments was significant (P < 0.001). 
Effects of CF on the gene expression of  
adipogenesis-associated genes 
The CF was the most efficient compound 
in decreasing TG accumulation and the most 
efficient in stimulating lipolysis. Taking in 
account that the influences of CF on adipo-
cyte differentiation has not been yet com-
pletely elucidated, the expression pattern of 
genes involved in the adipogenesis pathways 
was measured using the human RT2 Profiler 
PCR Array on CF-treated P20 cells. Volcano 
plot reported the log2(n-fold) values of sig-
nificantly (P < 0.05) up- and down-regulated
 
 
 
Figure 3: Determination of glycerol release (μM) in differentiating (P20) and mature (A7) adipocytes 
after incubation with all studied compounds. Results are depicted as mean (μM) ± standard error (SE). 
Capital letters above bars indicate the significant difference for P < 0.001 of the mean of glycerol re-
lease (μM) between the treatments. Capital letter A indicates that CF treatment significantly differs 
from OL, RE, SL, CA, TO, CU treatments and CTRLs; capital letter AB indicates that DHA treatment 
significantly differs from CA, TO, CU treatments and CTRLs; capital letter BC indicates that OL, RE 
and SL treatments significantly differ from CF and CTRLs; capital letter C indicates that CA treatment 
significantly differs from CF, DHA and CTRLs; capital letter CD indicates that TO and CU treatments 
significantly differ from CF, DHA and CTRLs; capital letter E indicates that CTRLs significantly differ 
from CF, DHA, OL, RE, SL, CA, TO, CU treatments. The glycerol release in P20 cells is significantly 
different (P < 0.001) from A7 cells.  
Compound: SL, Silybum marianum, CA, Citrus aurantium, RE, Resveratrol, TO, Taraxacum officinale, CU, Curcuma longa, CF, 
Caffeine, OL, Oleuropein, DHA, Docosahexaenoicacid 
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genes in comparison to CTRL cells (Figure 
4).  
The results revealed that 30 μg/mL of CF 
compound significantly (P < 0.05) up-
regulated the expression 11 genes (13 %) 
and down-regulated 11 genes (13 %) (Figure 
4). 
Among the genes that negatively affected 
adipogenesis DLK1, GATA2, GATA3, 
PRDM16, SFRP5, WNT1 and WNT3A were 
significantly (p < 0.05) up-regulated in P20 
cells treated with CF extract. Instead, 
CCND1, CDK4, CDKN1B, NR1H3, PPA-
RA, PPARD, PPARGC1B, and SREBF1 
were significantly (P < 0.05) down-regulated 
in the P20 cells treated with CF extract. 
 
DISCUSSION 
In this study, nine different bioactive 
compounds were assayed for their ability to 
influence the apoptosis, adipogenesis and 
lipolysis in primary visceral human pre-
adipocytes and adipocytes.  
DHA, RE and CF were the significantly 
strongest inhibitors of adipogenesis as evi-
denced by the percentage of triglyceride ac-
cumulation (Figure 2). Present data are in 
agreement with Kim et al. (2006) who 
demonstrated that DHA reduced lipid accu-
mulation in 3T3-L1 cells by inducing apop-
tosis and promoting lipolysis. However, in 
the present study, the lipolytic effect was 
more evident during differentiation (P20) 
than in mature adipocytes (A7), as also re-
ported on 3T3-L1 (Kim et al., 2008). Inter-
estingly, as evidenced by previous studies on 
P20 cells treated with Rosmarinus officinalis 
(Stefanon et al., 2015) and Rhodiola rosea 
(Pomari et al., 2015), the reduction of tri-
glyceride incorporation during differentia-
tion was coincident with an enhancement of 
lipolytic activity mediated by DHA and CF.
 
Figure 4: Volcano plot of adipogenesis human RT2 Profiler PCR array. PCR array analysis of gene 
expression in 30 μg/mL CF-treated P20 cells in comparison to P20 CTRL cells. The relative expres-
sion levels for each gene depicted as log2(n-fold) are plotted against –Log10(P-value). Red indicator = 
significantly up-regulated gene; Green indicator = significantly down-regulated gene. Red line = indi-
cates -Log10(P -value), p < 0.05. Treatment: CF, caffeine 
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RE at the concentration of 30 µg/mL, is 
known to suppress adipogenesis in 3T3-L1 
cells in comparison to CTRL cells (Santos et 
al., 2014). It is also demonstrated that RE 
extract induces apoptosis in 3T3-L1 pre-
adipocytes, adipocytes and in rat primary 
adipocytes (Rayalam et al., 2008). In the pre-
sent study RE was found to exert its apoptot-
ic function only in P20, but not in A7 cells 
(Figure 1). Of note, neither one compound 
was able to promote apoptosis in mature 
cells.  
Silibinin, the major active constituent of 
SL, has been recognized to inhibit adipocyte 
differentiation by inducing cell cycle arrest 
in the G0/G1 phase through the control of 
cell cycle regulators (Suh et al., 2015). SL-
treated P10 and P20 cells showed respective-
ly a 78.8 ± 13.5 % and 69.0 ± 4.2 % of TG 
accumulation in comparison to P20 CTRL 
cells and SL-treatment was significantly dif-
ferent from the DHA treatment (Figure 2). 
Other evidences suggested that the decrease 
of adipogenesis in human differentiated adi-
pocytes treated with silibinin was due to the 
promotion of a brown remodeling that, in 
comparison to control cells, was around 
74 % (Barbagallo et al., 2016), a value quite 
similar to present results. OL was the less 
active compound in reducing adipogenesis, 
although on 3T3-L1 cells it has been shown 
that OL exerts its anti-adipogenic effect dur-
ing the first 2 days of differentiation by ar-
resting or delaying the cell cycle (Drira e al., 
2011). On the other hand, OL was the com-
pound that in P20 cells exhibited the strong-
est effect on apoptosis together with SL and 
DHA treatments (Figure 1). These results are 
consistent with the data received on MCF-7 
cancer cells (Han et al., 2009). 
There is little information available con-
cerning the anti-obesity effect of dandelion 
and most of the literature consists of in vivo 
studies (Gamboa-Gómez et al., 2015). As 
reviewed by Schütz et al. (2006), TO con-
tains a wide array of phytochemicals distrib-
uted along the plant. In the leaves of dande-
lion are mostly present terpenes and phenolic 
compounds including coumaric acid, chico-
ric acid, monocaffeoyltartaric acid, cinnamic 
acid, caffeic acid, chlorogenic acid, and lute-
olin (González-Castejón et al., 2012). 
Among the effects studied on TO-treated 
P10, P20 and A7 cells, apoptosis was the 
most effective, respect to its effect on the TG 
accumulation and lipolysis. This is consistent 
with the strong induction of apoptosis ob-
served on pancreatic cancer cells treated with 
dandelion root extract (Ovadje et al., 2012). 
Since in the flowers and leaves the most 
abundant phenolic compounds are caffeic 
acid esters, such as chlorogenic acid, 
dicaffeoyltartaric (chicoric) acid and mono-
caffeoyltartaric acid, the observed effect of 
TO on differentiation can be comparable to 
that of CF. 
It is known that CF stimulates hydrolysis 
of TG through the activation of HSL and β-
adrenergic receptors (de Matteis et al., 2002). 
On 3T3-L1 cells was shown that caffeine 
(> 1 mM) suppresses adipocytes differentia-
tion by inhibition of C/EBPα and PPARγ 
expression, known as the main adipogenic 
transcription factors, and by promotion of 
the expression of negative regulators such as 
pre-adipocyte factor 1 (Pref-1, also known as 
DLK1) and KLF2 (Kim et al., 2016).  
Considering the results of cell differen-
tiation and lipolysis obtained from the CF 
treatment, the comparative gene expression 
analysis on P20 CF-treated and CTRL cells 
was performed (Figure 4). GATA2, GATA3, 
DLK1, WNT1 and WNT3A are among the 
genes significantly up-regulated by CF- 
treatment, which are known as strong inhibi-
tors of adipogenesis (Lowe et al., 2011; 
Moreno-Navarrete and Fernández-Real, 
2012). GATA2 and GATA3, two zinc-finger 
DNA-binding proteins transcription factors 
are typically expressed in pre-adipocytes and 
down-regulated during development. It was 
shown that GATA2 and GATA3 are able to 
bind PPARγ promoter thus preventing its 
transcription and blocking cells at the pre-
adipocyte stage (Tong et al., 2000). DLK1, 
known as pre-adipocyte factor 1 (Pref-1), is 
also highly expressed in pre-adipocytes and 
normally declines during differentiation. The 
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final target of the pathway downstream of 
DLK1 is Sox9, a transcription factor ex-
pressed in pre-adipocytes to suppress expres-
sion of C/EBPβ and C/EBP. Pref-1 prevents 
down-regulation of Sox9, which is required 
before adipocyte differentiation can proceed, 
resulting in inhibition of adipogenesis (Sul, 
2009). In fact, in CF-treated P20 cells, ex-
pression of CEBPB gene was found to be 
significantly down-regulated as well as ex-
pression of SREBF1 gene (Figure 4). The 
down-regulation of this transcription factor 
in turn reduced the expression of most of the 
genes involved in lipid accumulation and 
adipocyte differentiation. Many compounds, 
such as Chinese herbal medicine Yi-Gan-San 
and Vitisin A, have been described as inhibi-
tors of adipogenesis via SREBF1 regulation 
(Izumi et al., 2009; Kim et al., 2008). Re-
cently on 3T3-L1 pre-adipocytes was 
demonstrated that epiberberine, a natural al-
kaloid from the rhizome of C. chinensis, 
down-regulated protein expression of 
SREBF1 through the inhibition of 
Raf/MEK1/ERK1/2 and AMPKa1/Akt 
phosphorylation (Choi et al., 2015). SREBF1 
is also inhibited by betulin, promoting the 
interaction between SCAP (SREBF chaper-
one) and INSIG (insulin induced gene) 
which leads to the endoplasmic reticulum-
retention of SREBP (Tang et al., 2011). 
CDK4 is an important regulator of adi-
pocyte differentiation, promoting adipogene-
sis through PPARG activation (Abella et al., 
2005). In CF-treated P20 cells CDK4 was 
down-regulated and this agrees with the fact 
that CDK4 inactivation blocks adipocyte dif-
ferentiation (Chavey et al., 2013).  
WNTs are a large family of extracellular 
effectors which are known to play an im-
portant role in the suppression of adipogene-
sis through the canonical WNT signaling 
pathway (Gustafson and Smith, 2010), alt-
hough other mechanisms have been pro-
posed (Sethi and Vidal-Piug, 2010). Never-
theless, all mechanisms converge on inhibi-
tion of the main adipogenic transcription fac-
tors CEBPα and PPARγ. This can be 
achieved by stabilization of β-catenin which 
translocates into the nucleus and, binding 
TCF/LEF transcription factors, facilitates the 
induction of target genes, such as CCND1, 
which in turn directly inhibits CEBPα and 
PPARγ (Christodoulides et al., 2009). Such 
WNT activation could be caused by WNT1 
and WNT3A that were found up-regulated in 
CF-treated P20 cells (Figure 4). In fact, in 
differentiated 3T3-L1 adipose cells, WNT1 
led to inhibition of PPARγ (Grünberg et al., 
2014), activating WNT pathways similarly to 
WNT3A (Gustafson and Smith, 2010). 
However, in CF-treated P20 cells WNT5B 
and SFRP5 were also up-regulated (Figure 
4). WNT5B is known to promote adipogenic 
process (Nishizuka et al., 2008), while 
SFRP5 is recognized as WNT protein inhibi-
tor (Bovolenta et al., 2008) which prevents 
the activation of frizzled receptors and atten-
uates the noncanonical WNT signaling 
(Catalán et al., 2014). Its role is still contro-
versial and Wang et al. (2014) considered 
SFRP5 only a marker of mature adipocytes. 
Interestingly, treatment of P20 cells with 
Rosmarinus officinalis (Stefanon et al., 
2015), Rhodiola rosea (Pomari et al., 2015) 
and hydroxytyrosol (personal communica-
tion) activated the WNT signaling and led to 
the up-regulation of SFRP5 and WNT3A. 
WNT1 was also up-regulated with hydroxy-
tyrosol treatment, while WNT5B and 
WNT10B were up-regulated with Rhodiola 
rosea treatment. 
The screening of bioactive compounds 
on pre-adipocytes allowed to rank them for 
their anti-adipogenic effects. The results in 
differentiating cells showed that TO was the 
most active in inducing apoptosis; DHA, CF 
and RE were more efficient in lowering tri-
glyceride accumulation; CF, DHA and OL 
sufficiently increased lipolysis. According to 
these results, the differential expression of an 
array of genes involved in adipogenesis was 
analyzed after 20 days of pre-adipocytes 
treatment with CF and the results indicated a 
significant up-regulation of genes involved 
in WNT and GATA signaling and DLK1, 
which play a relevant role in the inhibition of 
adipogenesis. 
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These data suggest that bioactive com-
pounds with anti-adipogenic effects can be 
considered as potential candidates for further 
evaluations of their use as nutraceuticals in 
dietary supplements. 
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